Revvity (NYSE:RVTY) Issues FY 2026 Earnings Guidance

Revvity (NYSE:RVTY) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 5.350-5.450 for the period, compared to the consensus estimate of 5.320. The company issued revenue guidance of $3.0 billion-$3.0 billion, compared to the consensus revenue estimate of $2.9 billion.

Revvity Trading Down 1.7%

RVTY opened at $106.98 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.75. Revvity has a one year low of $81.36 and a one year high of $126.57. The company has a market cap of $12.13 billion, a P/E ratio of 53.76, a PEG ratio of 3.32 and a beta of 1.06. The business’s 50-day simple moving average is $104.09 and its 200-day simple moving average is $95.52.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. The firm had revenue of $772.06 million during the quarter, compared to analysts’ expectations of $759.81 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.42 earnings per share. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. As a group, equities research analysts expect that Revvity will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s dividend payout ratio is currently 14.07%.

Revvity declared that its board has initiated a share repurchase program on Monday, October 27th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 8.7% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

RVTY has been the subject of several research analyst reports. Guggenheim initiated coverage on Revvity in a report on Wednesday, October 15th. They issued a “neutral” rating for the company. Robert W. Baird increased their price target on shares of Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 28th. Evercore ISI reissued an “outperform” rating on shares of Revvity in a research report on Monday, January 5th. Barclays set a $118.00 target price on shares of Revvity and gave the company an “overweight” rating in a report on Tuesday. Finally, Jefferies Financial Group reissued a “hold” rating and set a $105.00 price target on shares of Revvity in a report on Monday. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Revvity currently has a consensus rating of “Hold” and an average target price of $110.55.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $1.70 (vs. consensus ~ $1.55) and revenue $772.1M, up 5.9% year-over-year, showing improving top- and bottom-line momentum. Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
• Positive Sentiment: Company raised FY2026 guidance — EPS guidance of $5.35–$5.45 and ~ $3.0B revenue guidance that sit above Street estimates, signaling management confidence in diagnostics strength. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
• Positive Sentiment: Immediate market reaction was positive as investors pushed the stock higher on the beat + outlook, supported by analyst notes highlighting the upside. Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Management call/transcripts and slide deck are available — useful for investors wanting detail on segment trends, margin drivers and cadence of growth. Revvity (RVTY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Valuation debate: recent share weakness has prompted DCF/analyst pieces arguing the stock may be attractive vs. intrinsic value, but opinions vary — this may support longer-term buyers more than short-term traders. Is Revvity (RVTY) Attractive After Recent Share Price Weakness And DCF Valuation Gap
• Negative Sentiment: Headwinds remain in academic research funding, which could pressure parts of the business even as diagnostics performs well — a risk to sustaining growth across all segments. Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Hedge Funds Weigh In On Revvity

A number of institutional investors and hedge funds have recently made changes to their positions in RVTY. CYBER HORNET ETFs LLC acquired a new position in shares of Revvity in the second quarter worth $32,000. MUFG Securities EMEA plc acquired a new position in Revvity in the 2nd quarter valued at about $34,000. Headlands Technologies LLC acquired a new position in Revvity in the 2nd quarter valued at about $49,000. EverSource Wealth Advisors LLC lifted its holdings in Revvity by 25.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 900 shares of the company’s stock valued at $87,000 after purchasing an additional 185 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in shares of Revvity during the 3rd quarter worth about $270,000. 86.65% of the stock is owned by institutional investors and hedge funds.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.